Israel Englander Supernus Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 252,743 shares of SUPN stock, worth $9.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

252,743

Previous 161,332 56.66%

Holding current value

$9.15 Million

Previous $4.32 Million 82.62%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $2.36 Million - $3.21 Million	91,411 Added 56.66%	252,743 $7.88 Million
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $3.35 Million - $4.36 Million	128,743 Added 395.05%	161,332 $4.32 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $3.85 Million - $4.99 Million	-141,999 Reduced 81.33%	32,589 $1.11 Million
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $934,087 - $1.22 Million	41,113 Added 30.8%	174,588 $5.05 Million
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $3.14 Million - $4.06 Million	104,938 Added 367.73%	133,475 $4.01 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $14.8 Million - $17.9 Million	-424,911 Reduced 93.71%	28,537 $1.03 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $14.1 Million - $17.2 Million	453,448 New	453,448 $16.2 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $6.19 Million - $8.36 Million	244,223 New	244,223 $7.06 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $2.61 Million - $3.02 Million	-91,662 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $8.59 Million - $11.2 Million	-325,862 Reduced 78.05%	91,662 $2.67 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $7.36 Million - $9.81 Million	312,679 Added 298.23%	417,524 $11.1 Million
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $2.25 Million - $2.8 Million	84,313 Added 410.64%	104,845 $3.23 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $281,902 - $367,115	11,673 Added 131.76%	20,532 $538,000
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $34,161 - $49,813	-1,930 Reduced 17.89%	8,859 $223,000
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $392,001 - $486,120	-19,406 Reduced 64.27%	10,789 $225,000
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $516,032 - $751,553	30,195 New	30,195 $717,000
Q1 2020 May 14, 2020	SELL	$14.45 - $24.69 $12.4 Million - $21.2 Million	-859,076 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $7.21 Million - $10.5 Million	361,525 Added 72.66%	859,076 $20.4 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $4.26 Million - $5.59 Million	167,378 Added 50.69%	497,551 $13.7 Million
Q2 2019 Aug 15, 2019	BUY	$29.96 - $38.87 $9.83 Million - $12.8 Million	328,036 Added 15350.3%	330,173 $10.9 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $13.7 Million - $17.8 Million	-457,171 Reduced 99.53%	2,137 $343,000
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $5.88 Million - $7.53 Million	179,305 Added 64.04%	459,308 $16.1 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $1.49 Million - $2.39 Million	48,255 Added 20.82%	280,003 $9.3 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $2.99 Million - $3.95 Million	69,931 Added 43.22%	231,748 $11.7 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $11.5 Million - $15.6 Million	-261,111 Reduced 61.74%	161,817 $9.69 Million
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $4.03 Million - $5.09 Million	-108,469 Reduced 20.41%	422,928 $19.4 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $113,276 - $132,571	-3,112 Reduced 0.58%	531,397 $21.2 Million
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $19.6 Million - $26.5 Million	534,509	534,509 $21.4 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account